Scinogy

Scinogy

Scinogy delivers automated, single‑use manufacturing platforms to make cell‑therapy production faster, cheaper, and commercially viable.

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

Scinogy delivers automated, single‑use manufacturing platforms to make cell‑therapy production faster, cheaper, and commercially viable.

OncologyImmunology

Technology Platform

Scinogy’s core technology is a modular, single‑use, closed‑system platform (Rotea) that integrates counter‑flow centrifuges, automated bag‑mixing, and real‑time process control to enable efficient, GMP‑compliant cell‑therapy manufacturing.

Opportunities

Rising demand for cost‑effective cell‑therapy manufacturing and the shift toward single‑use, automated platforms create strong growth potential for Scinogy.

Risk Factors

Intense competition from established CDMOs and the challenge of scaling services while maintaining regulatory compliance pose significant risks.

Competitive Landscape

Scinogy competes with large CDMOs such as Lonza and Thermo Fisher, differentiating itself through a focus on single‑use, highly automated systems that promise lower cost and faster turnaround.